drugset / Trial / NCT05667506

A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)

NCT05667506

Phase 1/2 Recruiting 47 enrolled Juventas Cell Therapy Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a multi-center, phase Ib/II trial to evaluate the safety and efficacy of CNCT19 treatment in Children and Adolescent (pediatric) patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-cell ALL).

Timeline

Start
2023-02-07
Primary completion
2025-05-30
Completion
2027-05-30

Drugs

EvaluationDrugModalityDoseRoute
Subject CNCT19 Cell therapy Intravenous
Background Cyclophosphamide Other / unclassified
Background Fludarabine Small molecule